



Ceramide-1-phosphate transfer protein (CPTP) regulation by phosphoinositides[#]

Received for publication, December 3, 2020, and in revised form, March 19, 2021. Published, Papers in Press, March 26, 2021.
<https://doi.org/10.1016/j.jbc.2021.100600>

Yong-Guang Gao¹, Xiuhong Zhai¹, Ivan A. Boldyrev², Julian G. Molotkovsky², Dinshaw J. Patel³, Lucy Malinina¹, and Rhoderick E. Brown^{1,*} 

From the ¹Hormel Institute, University of Minnesota, Austin, Minnesota, USA; ²Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russian Federation; ³Structural Biology Program, Memorial Sloan-Kettering Cancer Center, New York, New York, USA

Edited by Dennis Voelker

Ceramide-1-phosphate transfer proteins (CPTPs) are members of the glycolipid transfer protein (GLTP) superfamily that shuttle ceramide-1-phosphate (C1P) between membranes. CPTPs regulate cellular sphingolipid homeostasis in ways that impact programmed cell death and inflammation. CPTP down-regulation specifically alters C1P levels in the plasma and *trans*-Golgi membranes, stimulating proinflammatory eicosanoid production and autophagy-dependent inflammasome-mediated cytokine release. However, the mechanisms used by CPTP to target the *trans*-Golgi and plasma membrane are not well understood. Here, we monitored C1P intervesicular transfer using fluorescence energy transfer (FRET) and showed that certain phosphoinositides (phosphatidylinositol 4,5 biphosphate (PI-(4,5)P₂) and phosphatidylinositol 4-phosphate (PI-4P)) increased CPTP transfer activity, whereas others (phosphatidylinositol 3-phosphate (PI-3P) and PI) did not. PIPs that stimulated CPTP did not stimulate GLTP, another superfamily member. Short-chain PI-(4,5)P₂, which is soluble and does not remain membrane-embedded, failed to activate CPTP. CPTP stimulation by physiologically relevant PI-(4,5)P₂ levels surpassed that of phosphatidylserine (PS), the only known non-PIP stimulator of CPTP, despite PI-(4,5)P₂ increasing membrane equilibrium binding affinity less effectively than PS. Functional mapping of mutations that led to altered FRET lipid transfer and assessment of CPTP membrane interaction by surface plasmon resonance indicated that di-arginine motifs located in the α -6 helix and the α 3- α 4 helix regulatory loop of the membrane-interaction region serve as PI-(4,5)P₂ headgroup-specific interaction sites. Haddock modeling revealed specific interactions involving the PI-(4,5)P₂ headgroup that left the acyl chains oriented favorably for membrane embedding. We propose that PI-(4,5)P₂ interaction sites enhance CPTP activity by serving as preferred membrane targeting/docking sites that favorably orient the protein for function.

Lipid intracellular transport by vesicular and nonvesicular mechanisms helps maintain distinct lipid compositions associated with various cell organelles. Vesicular lipid transport involves budding and fission of vesicles from source membranes followed by trafficking and fusion with destination membranes. Nonvesicular lipid transport occurs *via* lipid transfer proteins (LTPs) that acquire and release their specific lipid cargoes during transient interaction with source and destination membranes (1–12). Variations in LTP transfer mechanisms include: *i*) shuttling of the amphitropic LTP back and forth through the aqueous milieu between membranes or *ii*) pendulum-like swinging of membrane-associated protein containing an LTP domain between closely apposed membranes. LTPs involved in the nonvesicular trafficking of sphingolipids (SLs) between membranes include ceramide transfer protein (CERT) (13, 14), certain SL activator proteins (15–18), and members of the glycolipid transfer protein (GLTP) superfamily (6–8, 19–21).

In the GLTP superfamily, evolutionary modifications have led to the two-layer, all- α -helical GLTP-fold becoming adapted for binding SLs containing either phosphate or sugar headgroups, thus distinguishing two GLTP families. Examples of the phosphate headgroup-specific family include human ceramide-1-phosphate transfer protein (CPTP) and the plant CPTP ortholog, accelerated cell death-11 protein (ACD11) (22, 23), whereas glycolipid-specific members include human GLTP and phosphatidylinositol-4-phosphate adapter protein-2 (FAPP2) (19, 24–30). In all cases, the two-layer α -helical GLTP-fold binds the SL in “sandwich-like” fashion such that the initial phosphate or sugar residue of the SL headgroup is bound to the protein surface and the hydrocarbon chains are enveloped within a hydrophobic pocket.

Emerging information indicates that GLTP superfamily members can function *in vivo* as molecular sensors and/or presentation devices involved in lipid metabolic regulation and signaling processes. GLTP, FAPP2, CPTP, and ACD11 have been implicated in the *in vivo* regulation of SL homeostatic levels and intracellular distributions (22, 23, 25, 31–34). In the case of human CPTP, siRNA-induced downregulation not only stimulates proinflammatory eicosanoid production but also triggers autophagy-dependent, inflammasome-mediated

[#] CPTP was originally known as *GLTPD1* prior to renaming by the HUGO Genome Nomenclature Committee; <http://www.genenames.org/>.

* For correspondence: Rhoderick E. Brown, reb@umn.edu.

Present address for Xiuhong Zhai: Research & Development Department, Aveda – The Estée Lauder Companies Inc, 4000 Pheasant Ridge Dr NE, Blaine, MN 55449, USA.

Phosphoinositide activation of the CPTP GLTP-fold

release of interleukin-1 β and -18 and pyroptosis by macrophage-like surveillance cells (22, 33). CPTP intracellular docking sites include the *trans*-Golgi, a C1P production site by ceramide kinase, as well as the plasma and nuclear membranes (22). CPTP depletion leads to approximately fourfold *in vivo* elevations of intracellular C1P (mostly 16:0-C1P species) that accumulate in *trans*-Golgi-enriched membrane fractions and decrease in plasma-membrane-enriched fractions. The elevated C1P levels in the TGN stimulate arachidonic acid release and drive downstream production of proinflammatory eicosanoids (22), presumably reflecting activation of cytoplasmic phospholipase A $_{2}\alpha$ via C1P binding to its C2 domain (35, 36).

GLTP superfamily members such as CPTP, ACD11, and GLTP lack known lipid-binding domains (LBDs) (e.g., PH, PZ, C1, C2) that target various proteins to select phosphoglycerides in intracellular membranes (37–43). To determine whether CPTP and related GLTP homologs contain targeting motifs for specific phosphoglycerides embedded in membranes, we investigated the regulatory effects exerted by various phosphoinositides (PIPs) on SL transfer by CPTP, ACD11, or GLTP and their membrane partitioning. We focused on PIPs present in the *trans*-Golgi (e.g., phosphatidylinositol-4-phosphate; PI-4P) and plasma membrane (phosphatidylinositol-4,5-bisphosphate; PI-(4,5)P $_2$) due to earlier

findings of CPTP enrichment at these intracellular sites (22). The data are consistent with PIP-specific headgroup interaction sites existing on CPTP but not GLTP that serve a dual role of enhancing SL transfer activity while also acting as preferred targeting/docking sites in specific membranes *in vivo*. Mapping of the PIP-selective motifs in C1P-specific GLTP-folds within membrane interaction regions reveals a role for the recently discovered ID-loop (α 3- α 4 helices connecting loop) (27).

Results

C1P transfer by CPTP is accelerated by PIP2 and PI-4P but not by PI-3P or PI

To assess whether certain PIPs can activate the SL transfer activities of various GLTP superfamily members (human CPTP, plant CPTP-ACD11, human GLTP), we used an established fluorescence resonance energy transfer (FRET) approach that monitors the real-time kinetics of the complete SL transfer reaction, *i.e.*, SL uptake by protein from “SL-source” membrane vesicles and SL delivery by protein to “destination” membrane vesicles (44). A more complete description of the FRET assay is provided as [Supporting information](#) and illustrated in [Fig. S1](#). Inclusion of various long-chain PIPs (PI-(4,5)P $_2$, PI-4P, PI-3P) or PI in SL-source




Figure 1. PIP effects on SL transfer by human CPTP and human GLTP. Traces in each panel show AV-SL emission intensity measured at 415 nm as a function of time resulting from FRET loss by AV-SL/Per-PC as AV-SL is transferred to POPC acceptor vesicles by CPTP (2 μ g). A, PI-(4,5)P $_2$ effects, B, PI-4P effects, C, PI-3P effects, and D, PI effects. E and F, summary of transfer rate changes induced by PI (red), PI-3P (green), PI-4P (magenta), PI-(4,5)P $_2$ (blue), or no PIP (gray) for CPTP (E) and GLTP (F). SL transfer rates are expressed as pmol/min transferred from SL source to POPC vesicles as a function of different PIP amounts (mol%) in the SL source vesicles. Error bars, S.D.




Figure 2. CPTP transfer activity stimulation by PI-(4,5)P₂ versus PS. A, traces show Me₄-BODIPY-SL emission intensity measured at 503 nm as a function of time resulting from FRET loss by Me₄-BODIPY-SL/C18-dil as Me₄-BODIPY-SL is transferred to POPC acceptor vesicles by CPTP (2 μg). CPTP transfer activity stimulation by PI-(4,5)P₂ is compared with that by PS. B, summary of CPTP transfer rates induced by PI-(4,5)P₂ (green) versus PS (red). C1P transfer rates are expressed as pmol/min transferred from C1P source to POPC vesicles as a function of PI-(4,5)P₂ or PS mol% in the SL source vesicles. Error bars, S.D.

POPC vesicles was found to exert different effects on the SL intermembrane transfer rates catalyzed by CPTP and GLTP (Fig. 1) and by ACD11 (Fig. S2) at physiologic ionic strength. The PIP concentrations in the model membranes were kept low to mimic the physiological situation (45) and the buffer contained EDTA to block potential effects by polyvalent

cations such as calcium (46). Notably, significant stimulation of C1P transfer rates occurred when 2, 4, or 6 mol% of PI-(4,5)P₂ or PI-4P was present in the C1P source (donor) vesicles (Fig. 1, A–E). In contrast, PI-3P and PI failed to stimulate and inhibited, respectively, the C1P transfer activity of CPTP and exerted minimal effects on ACD11 (Fig. S2). Notably, GalCer

Phosphoinositide activation of the CPTP GLTP-fold

transfer rates by GLTP were unaffected by PI and PI-3P as well as by 2 and 4 mol% PI-4P but were moderately decreased by 4 and 6 mol% PI-(4,5)P₂ (Fig. 1F).

To directly assess the ability of CPTP and ACD11 to interact with PI-(4,5)P₂ and PI-4P, protein–lipid overlay assays were performed (47). Fig. S3 shows that both CPTP and ACD11 exhibit relatively strong binding interactions with PI-(4,5)P₂ and PI-4P compared with various other anionic and zwitterionic phosphoglycerides, neutral lipids, and sulfatide. The observation of CPTP and ACD11 binding to phosphatidylserine (PS) and phosphatidic acid (PA) in the protein–lipid overlay assay, albeit moderate in intensity, is consistent with earlier findings for these two phosphoglycerides (48). In this previous study, SL transfer activity by CPTP and ACD11, but not GLTP, was found to be stimulated by membrane-embedded PS, but not by PA although no specific interaction site was identified. We therefore hypothesized that the CPTP membrane interaction region contains a specific binding site for targeting the PI-(4,5)P₂ and/or PI-4P headgroups. These PIP headgroups presumably would act as a tethering/activation site to help favorably orient CPTP for C1P uptake during membrane interaction while the PIP acyl chains remain embedded in the membrane interior. To test this idea, we

assessed whether C1P transfer by CPTP is stimulated by “soluble” PI-(4,5)P₂ with short acyl chains (di-octanoyl- PI-(4,5)P₂). We expected little or no activation by “soluble” PI-(4,5)P₂ due to its much weaker anchoring in the POPC bilayer vesicle and its high aqueous solubility (cmc > 4 mM; (49)) compared with di-oleoyl PI-(4,5)P₂. Indeed, replacing di-18:1 PI-(4,5)P₂ with di-8:0-PI-(4,5)P₂ in the SL-source vesicles resulted in no significant stimulation in C1P transfer rates by CPTP (Fig. S4). To test whether long-chain PI-(4,5)P₂ is a better stimulator of CPTP than long-chain PS, we compared in side-by-side fashion. The data in Figure 2 show that PI-(4,5)P₂ is a better stimulator of CPTP activity than PS at physiologically relevant PI-(4,5)P₂ membrane concentrations (≤6 mol% in POPC).

To quantifiably assess and compare the extent to which the long-chain PIPs, PS, and other anionic phosphoglycerides impact the membrane-binding affinity of CPTP, we relied on FRET involving CPTP Tyr/Trp (energy donor) and POPC membrane vesicles containing dansyl-phosphatidylethanolamine (PE) (energy acceptor). Figure 3, A and B show the FRET responses produced by CPTP adsorption to POPC vesicles as a function of their concentration when containing equal amounts of PI-(4,5)P₂, PI-4P,




Figure 3. Anionic phosphoglyceride effects on the membrane equilibrium binding by CPTP and PI-(4,5)P₂ effect on wtCPTP association/dissociation to/from POPC/C1P or POPC vesicles. In A and B, traces show dansyl-PE emission intensity measured at 513 nm resulting from FRET by CPTP Trp/Tyr (2 μg; excit. 285) as a function of increasing concentration of POPC vesicles containing various PIPs and other anionic phosphoglycerides. In C and D, traces show surface plasmon resonance (SPR) data for CPTP adsorption and desorption to/from immobilized membrane vesicles of differing lipid composition. C, immobilized POPC vesicles containing C1P (10 mole%); D, immobilized POPC vesicles containing no C1P. In both panels, PI-(4,5)P₂ amounts of 0 (black trace), 5 mol% (red trace), and 10 mol% (cyan trace) are shown for vesicles adsorbed to a Sensor Chip L1 (see Experimental procedures). wtCPTP injections are indicated by arrows and switches to buffer wash, by the second arrows in each trace.

PI-3P, or PI (Fig. 3A) as well as PS, PA, or PG (Fig. 3B). Analyses of the binding isotherms resulted in the relative equilibrium binding affinity constants (K_d) shown in Table 1. The K_d values for POPC vesicles containing PI-(4,5)P₂, PI-4P, and PI-3P are six- to seven-fold lower than that for pure POPC vesicles (Table 1), whereas the K_d for POPC vesicles containing PI is only 2.3-fold lower. Interestingly, including PS and PA yielded relative K_d values even lower than the PIP values, which are comparable to that elicited by the presence of PG. The binding response for POPC vesicles containing PS and PA (relative to pure PC vesicles) agrees with earlier qualitative data showing that both PS and PA enhance membrane binding by plant CPTP, *i.e.*, ACD11, but only PS stimulates transfer activity of ACD11 and CPTP, but not GLTP (48).

To determine the impact of long-chain PI-(4,5)P₂ on CPTP association and dissociation to/from PC membranes, surface plasmon resonance (SPR) analyses were performed. SPR provides real-time insights into protein adsorption and desorption to/from the membrane associated with SL uptake or release, *i.e.*, transfer “half-reactions.” The insights help understand the protein-mediated lipid transfer process, which involves: i) LTP association with the membrane; ii) lipid uptake by membrane-associated LTP; iii) LTP/cargo-lipid desorption from the membrane; iv) LTP/cargo-lipid association with acceptor membrane; v) LTP release of lipid cargo into the membrane; vi) lipid-free LTP desorption from acceptor membrane (19, 50, 51). Further complicating the situation is the proposed involvement of transient protein dimerization during membrane interaction (7). SPR experiments were initiated by introduction of CPTP into the flow cell after adsorbing and equilibrating the lipophilic sensor chip with vesicles of differing lipid composition. As shown in Figure 3, C and D, inclusion of 5 or 10 mol% PI-(4,5)P₂ in POPC vesicles significantly enhanced CPTP adsorption both in the presence or in the absence of C1P.

Location of the PI-(4,5)P₂ interaction site(s) on CPTP

Di-Arg motifs are known to function as PI-(4,5)P₂ interaction sites in the Rho GTPase, Cdc42 (52) and as PI-3P and PI-(3,5)P₂ interactions sites in the PROPPIN Atg18 (53). Human CPTP contains two di-Arg motifs but GLTP, which is not activated by PIP₂, has none. The two di-Arg motifs in wtCPTP are located near the C1P-binding site that resides within the membrane interaction region of the protein. To assess the

potential for these two di-Arg motifs to function as PI-(4,5)P₂ interaction site(s) on human CPTP, we examined CPTP docking to membranes as modeled by the Orientation of Proteins in Membranes (OPM) approach (54). Figure 4A illustrates membrane interaction by CPTP prior to sphingolipid uptake with respect to overall protein orientation and penetration as well as initial docking regions. The embedding of α -helix 6 in the membrane is well supported by experimental data (7, 19, 29, 55, 56). One di-Arg motif (R155-R156) of CPTP is located in α -helix 6 near Trp152, which has previously been identified as a key residue for membrane interaction by GLTP superfamily members (22). The OPM-guided model of CPTP orientation during interaction with the bilayer interface reveals that the R155-R156 di-Arg motif in α -helix 6 is favorably positioned for interaction with the PI-(4,5)P₂ headgroup in the bilayer surface (Fig. 4A).

The other di-Arg motif (R96-R97) is located within the α -3/ α -4 helices connecting loop, also known as the ID-loop (27). The OPM-guided model indicates that the R96-R97 di-Arg motif in the α 3- α 4 helix connecting loop of CPTP is also reasonably well-positioned for interaction with the PI-(4,5)P₂ headgroup. The ID-loops of GLTP superfamily members vary in length (Fig. 4B) and conformation but generally have stabilizing intraloop interactions (27). In this regard, the α 3- α 4 helix connecting loop (ID-loop) of CPTP and ACD11 (Fig. S5) appears better suited for PI-(4,5)P₂-mediated membrane interaction than that of GLTP (Fig. 4C). Notably, di-Arg motifs do not occur in the ID-loop or α -helix 6 of GLTP but a single Lys residue is present in the α -6 helix.

To experimentally test for involvement of the two CPTP di-Arg motifs in binding to PI-(4,5)P₂, we generated ID-loop mutant R96A/R97A as well as helix-6 mutant R155A/R156A (Fig. 4C). Yet, we were able to successfully express and purify only CPTP R96A/R97A due to insolubility issues for CPTP R155A/R156A. To circumvent this issue, Arg155 was mutated to glutamine (Q), whereas Arg156 remained unaltered to mimic the situation in GLTP, which shows no transfer activity stimulation by PI-(4,5)P₂ and contains α -helix 6 residues, Q145-K146 at the structural positions corresponding to R155-R156 in CPTP (Fig. 4B). Residues A83-E84 of the GLTP α 3/ α 4 helix connecting loop (ID-loop) are located at structural positions corresponding to R96/R97 of CPTP (27).

Assessment of the CPTP-R96A/R97A and CPTP-R155Q transfer activities of BODIPY-C1P to POPC acceptor vesicles from donor vesicles containing no PIP or 4 mol%, PI, PI-4P, or PI-(4,5)P₂ is shown in Figure 5. The mutations produced measurable, moderate effects on the baseline transfer activities from POPC donor vesicles lacking PIPs (Fig. 5A). A similar impact of the mutations on C1P transfer was observed when POPC donor vesicles contained 4 mol% PI (Fig. 5B). However, mutation of the di-Arg site in either α -helix 6 or in the α 3- α 4 helix connecting loop (ID-loop) not only eliminated the activation effects observed for 4 mol% PI-4P and PI-(4,5)P₂ on wtCPTP but also dramatically slowed C1P transfer from POPC vesicles containing these PIPs (Fig. 5, C and D) with a stronger effect exerted by PI-(4,5)P₂. Measurements performed using donor vesicles containing either 2 or 6 mol%, PI, PI-4P, or PI-

Table 1
Relative equilibrium binding affinity of CPTP for POPC vesicles containing different anionic phosphoglycerides

Lipid	K_d (μ M)	Relative to POPC
PI-(4,5)P ₂	0.26 \pm 0.04	6.8
PI-4P	0.26 \pm 0.03	6.8
PI-3P	0.29 \pm 0.04	6.1
PI	0.75 \pm 0.09	2.3
PS	0.07 \pm 0.02	25.1
PA	0.11 \pm 0.02	16.0
PG	0.24 \pm 0.04	7.3
PC	1.76 \pm 0.20	1.0

Anionic phosphoglycerides = 10 mol%.

Phosphoinositide activation of the CPTP GLTP-fold

(4,5)P₂ (Fig. S6) resulted in similar trends albeit moderately weaker or stronger in absolute magnitude compared with 4 mol % PI-(4,5)P₂.

To directly assess the extent to which the mutations impacted protein association and dissociation with PC membranes, SPR analyses were performed. We focused on PI-(4,5)P₂ because of the stronger stimulatory response elicited by this PIP and because of our previous findings showing CPTP transfer of C1P from the *trans*-Golgi to the plasma membrane (22) where PI-(4,5)P₂ is known to localize intracellularly (45). Figure 6 shows the SPR responses for wtCPTP and various ID-loop or helix 6 mutants. Enhanced association by wtCPTP was observed when the immobilized POPC/C1P vesicles contained PI-(4,5)P₂ (Fig. 6A). Notably, when the immobilized POPC/C1P vesicles lacked PI-(4,5)P₂, replacement of Arg in either the ID-loop (R96A, R97A, and R96A/R97A) or helix-6 (R155Q) resulted in diminished CPTP association compared with that of wtCPTP (Fig. 6, A–E; black data curves). This finding is not surprising and likely reflects the well-established role for Arg residues in nonspecifically enhancing protein–membrane interactions *via* “snorkeling” involving side-chain guanidinium interactions with the negatively charged phosphate residues of phosphoglycerides such as PC (57–59). Nonetheless, the enhanced association response for POPC bilayers containing PI-(4,5)P₂ remained strong for CPTP-R155Q and CPTP-R97A (Fig. 6, B and D) but was significantly diminished for CPTP-R96A (Fig. 6C). In contrast, association of the CPTP double mutant (R96A/R97A) with immobilized POPC/C1P vesicles containing PI-(4,5)P₂ was clearly negatively impacted (Fig. 6E). Similar overall trends also were observed for both wtCPTP and the mutants when immobilized POPC vesicles lacked C1P but contained PI-(4,5)P₂ (Fig. S7). Taken together, the data support involvement of both di-Arg sites within the CPTP membrane interaction region for mediating binding with PI-(4,5)P₂ embedded in POPC membranes. The CPTP di-Arg site functionality occurs regardless of the presence or absence of C1P. Maximum stimulation of CPTP transfer activity by PI-(4,5)P₂ requires both Arg residues of the R96-R97 site in the ID-loop.

Discussion

Our investigation provides evidence for PIP regulatory sites existing in the membrane-interaction region of CPTP, a single-domain GLTP superfamily member that transfers C1P between membranes (6–8, 22, 23). Previously, identification of lipid regulators controlling the membrane interaction of 4-phosphate adaptor protein-2 (FAPP2), a multidomain GLTP superfamily member that transfers GlcCer from the *cis*-Golgi, focused on its N-terminal pleckstrin homology (PH) domain that interacts with PI-4P without attention to its GLTP homology (GLTPH) domain (25, 60). Thus, the possibility for PIP regulation *via* direct interaction with GLTPH domain or with single-domain GLTP superfamily members has remained unclear.

Our data show that PI-4P and PI-(4,5)P₂, but neither PI-3P nor PI, stimulate the SL transfer activity of human CPTP and

plant ACD11 C1P-specific GLTP-folds at physiologic ionic strength and in the absence of Ca²⁺. The stimulation by PI-4P and PI-(4,5)P₂ is not duplicated for human GLTP, a glycolipid-specific GLTP-fold. X-ray structures of CPTP and ACD11 complexed with C1P show a conserved cationic Arg/Lys triad interacting with the C1P headgroup and a Asp-His “clasp” interacting with the ceramide amide moiety along with additional Arg and Lys residues in the membrane interaction region surrounding the SL headgroup recognition site (6, 7, 22, 23). In addition to protein structural features and simple charge–charge effects, membrane-related factors need also to be considered when evaluating lipid transfer processes. CPTP interacts only with PIPs and C1P located in the outer leaflet of the bilayer vesicle. The membrane interactions by GLTP homologs occur in a moderately penetrating and minimally perturbing manner that leaves the sphingolipid pool in the inner leaflet of the vesicle bilayer inaccessible to protein (50, 51, 61, 62). Thus, neither GLTP nor CPTP nor ACD11 can access the inner bilayer leaflet or promote transbilayer migration of their target SLs. Spontaneous transbilayer migration of C1P is highly restricted due to the unfavorable energetics of moving the phosphate polar headgroup through the nonpolar hydrocarbon matrix.

In mammals, C1P is produced anabolically by ceramide kinase at the *trans*-Golgi cytosolic face (63, 64) and then is transported to other intracellular sites such as the plasma membrane cytosolic surface (22). Accordingly, C1P is localized initially only in the C1P source (donor) vesicles and not in the destination (acceptor) vesicles. *In vivo*, certain PIPs reside in specific intracellular membranes that face the cytosol (45, 65–68), where they can potentially be targeted by various peripheral amphitropic proteins including CPTP or GLTP. PI-4P resides in the *trans*-Golgi, plasma membrane, and endosome/lysosome (66). PI-(4,5)P₂ localizes predominantly to the plasma membrane (45). PIP concentrations in POPC-SL source vesicles were kept low (≤10 mol %) to mimic the PIP physiological situation.

The selective *stimulation* of C1P transfer activity by anionic PI-4P and PI-(4,5)P₂, but not by PI-3P or PI, prompted us to consider the existence of a PIP-headgroup specific surface-binding site(s) located within the CPTP membrane interaction region. Because replacement of di-18:1 PI-(4,5)P₂ with short-chain (di-8:0) “soluble” derivatives fails to stimulate C1P transfer by CPTP, the PIP headgroup needs to remain firmly associated with the C1P-source membrane to activate C1P transfer by CPTP. It is noteworthy that the equilibrium binding constants for CPTP with POPC vesicles containing various anionic phosphoglycerides do not correlate with their capacity to stimulate or slow SL transfer activity. For instance, the equilibrium membrane-binding constant for POPC vesicles containing PI-(4,5)P₂ is three- to four-fold larger than that for POPC vesicles containing PS (Table 1). Yet, PI-(4,5)P₂ is the better stimulator at low membrane concentrations. This situation likely reflects the complex, multistep mechanism of CPTP action. It also is worth remembering that the FRET efficiency is affected by both distance and orientation of the fluorophores. In CPTP, two of three Trp residues are located




Figure 4. OPM-based structural model for membrane interaction by CPTP. *A*, orientation of peripheral protein during membrane interaction (OPM) modeling for CPTP complexed with 16:0 C1P (PDB: 4k84; 1.90 Å resolution) reveals favorable positioning of the α 3- α 4 helices connecting loop (“ID-loop”) and the α 6-helix and their respective R96/R97 and R155/R156 di-Arg motifs for acting as potential interaction sites for PIP headgroup binding. *B*, OPM modeling for GLTP complexed with 24:1 GalCer (PDB: 4euk; 1.85 Å resolution), which is not stimulated by PIPs, has A83/E84 in the α 3- α 4 helices connecting loop (“ID-loop”) and Q143/K144 in α 6-helix at structurally equivalent positions as di-Arg in CPTP. *C*, sequence alignments for the di-Arg motif regions of the ID-loop and α 6-helix in CPTP compared with the same regions in GLTP, ACD11, and FAPP2. Alignments are derived from comparisons of their crystal structures (28).

Phosphoinositide activation of the CPTP GLTP-fold




Figure 5. Mutation mapping identifying di-Arg motifs as PIP sites affecting CPTP-mediated C1P Transfer. Traces in each panel show BODIPY-SL emission intensity at 503 nm as a function of time (due to BODIPY-SL/C18-Dil FRET loss) when BODIPY-SL transfers to POPC vesicles. SL donor vesicles compositions are: A, POPC; B, POPC/PI (96:4); C, POPC/PI-4P (96:4); and D, POPC/PI-(4,5)P₂ (96:4). In each panel, wtCPTP (black trace), CPTP-R96A/R97A (red trace), and CPTP-R155Q (blue trace) are compared. Data for 2 mol% and 6 mol% POPC/PI-(4,5)P₂ are provided in Fig. S6. E, Comparison of C1P transfer rates for data shown in panels A, B, C, and D. The SL transfer rates are expressed as pmol/min transferred from SL source POPC vesicles. Error bars, S.D.

close to the C1P-binding site. We conclude that the enhanced partitioning driven by PI-3P, PI, PA, and PG leaves CPTP in unfavorable membrane orientations that slow C1P uptake/transfer. By contrast, more favorable orientations that help enhance C1P uptake/transfer and (increases FRET efficiency) are elicited by PS, PI-(4,5)P₂, and PI-4P. We propose that these phosphoglycerides function as membrane tethering sites that engage and orient CPTP in ways that optimize function while also possibly helping to target certain intracellular locations. This thinking led us to look beyond simple CPTP surface charge near the C1P-binding site and consider directly testing for the existence of a PI-(4,5)P₂-headgroup specific surface-binding site within the membrane interaction region of CPTP.

Mapping of the PI-(4,5)P₂ headgroup-binding sites by mutational functional analyses, OPM membrane modeling, and HADDOCK modeling indicate involvement of two di-Arg sites within the CPTP membrane interaction region. Whereas OPM helps identify the molecular regions in peripheral proteins (e.g., helix 6 and the ID-loop of CPTP) that interact with membranes (Fig. 4 & Fig. S5), HADDOCK modeling provides a molecular picture of how the di-Arg motifs in helix 6 and the ID-loop are likely to engage the phosphorylated inositol ring of PI-(4,5)P₂ (Fig. 7). It is noteworthy that these di-Arg motifs are lacking in α -helix 6 and in the ID-loop (α 3- α 4 helix connecting loop) of human GLTP, which is not activated by PI-(4,5)P₂. Haddock modeling is an information-driven, flexible docking approach that differs from *ab initio* docking methods by

encoding information from identified or predicted protein interfaces in ambiguous interaction restraints (AIRs) to drive the docking process (69, 70). HADDOCK is able to address various modeling problems including protein–ligand, protein–protein, and protein–nucleic acid complexes. In our case, Haddock modeling reveals specific interactions by the PI-(4,5)P₂ headgroup and acyl chains oriented favorably for membrane embedding (Fig. 7).

Novel features of CPTP PIP₂ motifs compared with lipid-binding domains (LBDs)

In some respects, the CPTP PIP interaction sites function analogously to LBDs. Such domains (e.g., C1, C2, PH, PX, FYVE) exist as modular structural elements within multidomain proteins. LBDs target the phosphoglyceride headgroup and contain no hydrophobic pocket for enveloping the lipid aliphatic chains. This arrangement keeps the lipid chains embedded in the membrane while the protein interacts with the phosphoglyceride headgroup. LBDs function as autonomous membrane docking modules that help selectively tether various peripheral, amphitropic proteins to select intracellular membrane sites while sometimes regulating nearby catalytic domains (37–43). In contrast, single-domain CPTP harbors both PI-(4,5)P₂ docking sites very near to its C1P cargo binding site, enabling coincident site functionality within the CPTP membrane interaction region. The somewhat differing responses of each PI-(4,5)P₂ headgroup-binding site to




Figure 6. Mutation mapping showing di-Arg motif involvement in CPTP partitioning to POPC/C1P vesicles containing PI-(4,5)P₂. SPR assessments of CPTP mutant adsorption and desorption to/from immobilized membrane vesicles of differing lipid composition. *A*, wtCPTP; *B*, CPTP-R155Q; *C*, CPTP-R96A; *D*, CPTP-R97A; *E*, CPTP-R96A/R97A. Injections are indicated by the first arrows and switches to buffer wash, by the second arrows in each trace. In all panels, PI-(4,5)P₂ amounts of 0 (black trace), 5 mol% (red trace), and 10 mol% (cyan trace) are shown for vesicles adsorbed to the Sensor Chip L1 (see [Experimental procedures](#) for details).

mutation further suggest that cooperativity may play a role in optimally orienting CPTP for C1P uptake/release. The close proximity of the PIP targeting motifs to the C1P-binding site raises the possibility that CPTP interaction with long-chain PIPs embedded in C1P-containing membranes could facilitate protein conformational changes that enhance C1P uptake or release. The preceding ideas will need future comprehensive study.

What is clear is that PI-(4,5)P₂ interacts with CPTP in a fundamentally different way compared with LBDs and other peripheral proteins. While cationic residues (Arg, Lys) play significant roles in all such proteins, there is no conserved structural arrangement of these residues, which generally are located at junctures of protein structural elements. [Fig. S8](#)

illustrates by showing the structures of the PI-(4,5)P₂-binding sites involving β -strand crevices such as that in rabphilin C2A domain (β 3/4 strand residues) and the two sites in Arf GAP ASAP1 PH domain (β 1/2 & β 3/4 strand and β 6/7 loop residues = canonical site; β 1/2 opposite side residues adjacent to β 5/6 loop residues = atypical site). Helix clusters involving three and two helices that favorably converge residues for PI-(4,5)P₂ binding occur in ENTH epsin and metavincludin and are shown in [Fig. S8, C and D](#), respectively. These situations contrast that of the CPTP PI-(4,5)P₂ interaction sites where its two di-Arg motifs are self-contained within single elements (α 6-helix or α 3/ α 4 helix connecting loop) that each reside within the protein's membrane interaction region.

Phosphoinositide activation of the CPTP GLTP-fold

Physiological perspectives

The discovery of PI-(4,5)P₂- and PI-4P-induced enhancement of C1P-specific GLTP homolog action provides insights into how CPTP and ACD11 could be targeted to and site-specifically stimulated by certain membranes in animal and plant cells, respectively. Intracellularly, PIPs occur in the cytosol-facing surfaces of the plasma membrane, endosomes, and Golgi enabling docking and activation by important cytoplasmic signaling and fusogenic proteins with specific PIP-binding domains (45, 71). PI-4P recruits not only coat proteins and accessory factors required for vesicular transport from the Golgi but also other lipid-binding/transfer proteins such as OSBP, CERT, and FAPP2, which contain PH domains that bind to PI-4Ps, to mediate their Golgi localization. PI-(4,5)P₂ aids in the activation of plasma membrane channels/transporters, serves as a precursor for the generation of second messengers, and functions as a plasma membrane recruiter for cytosolic peripheral proteins such as those shown in Fig. S7 (67, 72–76). Human CPTP, a regulator of proinflammatory eicosanoid production, autophagy, inflammasome assembly, and pyroptosis, and ACD11, a regulator of accelerated cell death in plants, can now be added to this growing list of amphitropic peripheral membrane proteins. Our findings

support earlier observations (22, 33) showing CPTP enrichment at the *trans*-Golgi and on the cytoplasmic surfaces of endosomes and plasma membrane, sites where PIPs also reside.

Conclusions

Significant stimulation of human and plant C1P-specific lipid transfer proteins, at physiological ionic strength and in the absence of divalent cations (*e.g.*, calcium), occurs when certain PIPs (PI-4P and PI-(4,5)P₂), but not PI-3P nor PI, are embedded in POPC bilayer vesicles. Notably, “soluble” PIPs that do not remain firmly embedded in the bilayer matrix produce no stimulatory effect on C1P transfer. By contrast, glycolipid-specific human GLTP activity is not activated by any of the three PIPs tested (PI-4P, PI-(4,5)P₂). CPTP binding to the PI-(4,5)P₂ headgroup involves di-Arg motifs located in α -helix 6 and in the α 3- α 4 helices connecting loop (“ID-loop”) of the GLTP-fold. While α -helix 6 involvement in membrane docking by GLTP superfamily proteins is well established, elucidation of a unique membrane interacting role for the ID-loop of C1P-specific GLTP superfamily members is novel. The binding sites for PI-(4,5)P₂ (and possibly PI-4P) function are proposed to help optimally orient and tether CPTP (and ACD11) on the membrane surface for uptake and release of C1P during the SL transfer process. The findings are important because C1P-specific lipid transfer proteins are known regulators of inflammation and programmed cell death (8), although potential mechanisms by which these proteins can be targeted to certain intracellular destinations have remained largely unknown until now.

Experimental procedures

1-Palmitoyl-2-oleyl-*sn*-glycero-3-phosphocholine (POPC), 1,2-dioleoyl-*sn*-glycero-3-phospho-(1'-myo-inositol) (PI); 1,2-dioleoyl-*sn*-glycero-3-phospho-(1'-myo-inositol-4'-phosphate) (di18:1 PI-4P); 1,2-dioctanoyl-*sn*-glycero-3-phospho-(1'-myo-inositol-4'-phosphate) (di8:0 PI-4P); 1,2-dioleoyl-*sn*-glycero-3-phospho-(1'-myo-inositol-4',5'-bisphosphate) (di18:1 PIP₂), and 1,2-dioctanoyl-*sn*-glycero-3-phospho-(1'-myo-inositol-4',5'-bisphosphate) (di8:0 PIP₂) were purchased from Avanti Polar Lipids and used without further purification. Lipid labeled with 3-perylenoyl (Per), anthrylvinyl (AV), or 4,4-difluoro-1,3,5,7-tetramethyl-4-bora-3a,4a-diaza-*s*-indacene (Me₄-BODIPY) fluorophores (*e.g.*, Per-PC, AV-C1P, AV-GalCer, Me₄-BODIPY-C1P, Me₄-BODIPY-GalCer) were synthesized by lyso-lipid reacylation with omega-labeled 9-(3-perylenoyl)-nonanoyl, (11*E*)-12-(9-anthryl)-11-dodecenoyl, or 15-(Me₄-BODIPY)-pentadecanoyl chains followed by purification (77–79). 1,1'-di-octadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiIC₁₈) was purchased from Molecular Probes of Thermo Fisher Scientific.

Recombinant protein purification

Cloning, expression, and purification of ACD11, CPTP, and GLTP have been described previously (22, 23, 80–82). Briefly,




Figure 7. Haddock modeling of PIP₂ interaction with CPTP di-Arg sites. A, Haddock model of PI-(4,5)P₂ interaction with the R155/R156 motif of CPTP. B, Haddock model of the PI-(4,5)P₂ interaction with the R96/R97 motif of CPTP. The representative complex structures come from the top cluster (with the lowest HADDOCK score), which was Cluster 1 for R555/R156 and Cluster 3 for R96/R97 (see Fig. S9).

the open reading frames (ORFs) for human *CPTP* (GenBank JN542538 & NP_077792.2), *Arabidopsis acd11* (NCBI NP_181016.1) and human *GLTP* (GenBank AF209704) were ligated into pET-28 vector (kanamycin-resistant; Invitrogen) modified with small ubiquitin-like modifier (SUMO) protein ORF, which were then used to transform BL21 (DE3)-pLysS cells for expression of proteins N-terminally tagged with 6xHis-SUMO (22, 23). Transformed cells were grown in Luria-Bertani medium at 37 °C for 6 h, induced with 0.1 mM IPTG, and then incubated 16 to 20 h at 15 °C. Affinity protein purification from soluble lysate was accomplished by Ni-NTA affinity chromatography. Cleavage of N-terminal 6xHis-SUMO tag was carried out with SUMO protease, Ulp1, overnight at 4 °C. Affinity repurification by Ni-NTA chromatography followed by FPLC gel filtration chromatography (HiLoad 16/60 Superdex-75 prep grade column; GE Healthcare), equilibrated with buffer containing 25 mM Tris-HCl, pH 8.0, 100 mM NaCl and 1 mM DTT, yielded proteins with native sequences. Pooled peak fractions were concentrated by centrifugal concentrators (Vivaspin; 10 kDa cutoff). Protein purity was confirmed by SDS-PAGE (81) before flash freezing the pure proteins in buffer containing 50% glycerol and storing at -20 °C.

Protein-mediated sphingolipid intermembrane transfer

Real-time intermembrane transfer rates of fluorescent sphingolipids by CPTP, ACD11, and GLTP were obtained by Förster resonance energy transfer (FRET) using a SPEX FluoroLog3 spectrofluorimeter (Horiba Scientific), with excitation and emission band passes of 2 nm and a stirred (~100 rpm), temperature-controlled (25 °C ± 0.1 deg. C) sample cuvette holder (44, 48, 61). All fluorescent lipids were localized initially to the sphingolipid-source (donor) POPC vesicles formed by rapid ethanol injection. Excitation of AV- (370 nm) or BODIPY-sphingolipid (460 nm) results in minimal emission at 415 nm or 503 nm, respectively due to resonance energy transfer to nearby Per-PC or C18-DiI, respectively. Addition of approximately tenfold excess of sonicated POPC acceptor vesicles or POPC/DHPC bicelles produces little change in fluorescence signal, yielding a “no protein” baseline response for spontaneously transferred AV-sphingolipid, which is very slow (83, 84). Protein addition triggers a sudden, hyperbolic increase in AV or BODIPY emission intensity (415 nm or 503 nm, respectively) reflecting the FRET decrease due to protein transport of fluorescent sphingolipid to receiver (acceptor) vesicles and separation from nontransferable Per-PC or C18-DiI lipids in sphingolipid-source vesicles. The use of the two different FRET fluorophore donor/acceptor pairs shows that the structural features of any one set of fluorophore probe pairs are not responsible for the basic experimental outcomes. Maximum sphingolipid transfer, ΔF , is the difference in emission intensity in the absence and presence of protein late in the kinetic time course (>15 min) and arises from the fluorescent sphingolipid present in the outer leaflets of the sphingolipid-source vesicles and accessible to the

protein. Addition of Tween-20 detergent after extended incubation provides a measure of maximum intensity achievable at “infinite” fluorophore separation. Nonlinear regression analyses using ORIGIN 7.0 software enable quantification of the initial lipid transfer rate, v_0 , for the first-order exponential transfer process. Standard deviations were calculated at 95% confidence interval. R2 values for all estimates were >0.96.

Vesicle preparation

Acceptor POPC vesicles and donor vesicles composed of POPC (97.5 mol%), AV-lipid (1 mol%), and Per-PC (1.5 mol%) or POPC (97.5 mol%), BODIPY-15-GalCer (1 mol%), and DiI-C18 (1.5 mol%) were prepared as described in (61). Acceptor vesicle diameter averaged 25 to 30 nm. The final acceptor vesicle concentration in the FRET lipid transfer assay was ~85 μM, which was tenfold higher than that of the donor vesicles. Buffer contained 10 mM K phosphate (pH 6.6), 150 mM NaCl, and 0.2% EDTA.

FRET equilibrium binding affinity measurements

Partitioning of CPTP to membrane vesicles was monitored by FRET using Trp/Tyr emission of CPTP as the energy donor and POPC vesicles containing dansyl-PE (2 mol%) and (10 mol % of the phospholipid to be tested) as energy acceptors as described in (50). Vesicles were formed by mixing the POPC, dansyl-PE, and other lipids, drying under a stream of nitrogen and placing under vacuum for ~2 h, before suspending in ethanol. Binding reactions included CPTP (0.5 μM) and various amounts of vesicles formed by rapid ethanol injection (concentration from 0.1 to 5 μM) into 2 ml of stirred buffer containing 10 mM K phosphate (pH 6.6), 150 mM NaCl, and 0.2% EDTA. FRET measurements were performed at 25 °C in a temperature-controlled (±0.1 °C) cuvette (NesLab RTE-111, Thermo Fisher) using a SPEX FluoroLog-3 spectrofluorimeter (Horiba Scientific). Excitation and emission wavelengths were 284 nm and 513 nm with band-pass settings of 5 and 10 nm, respectively. FRET was calculated as $(I_{\text{obs}} - I_{\text{min}})/(I_{\text{max}} - I_{\text{min}})$, where I_{min} is the dansyl emission in the absence of vesicles and I_{max} is the maximal energy transfer obtained from the binding curve. FRET data were plotted as relative fluorescence signal *versus* PC concentration of the vesicles and fit to the equation described in (50).

Surface plasmon resonance of protein partitioning to membranes

Assays were performed using a Biacore T200 system (GE Healthcare Bio-Sciences Corp). POPC/SL/phosphoinositide vesicles (1 mM) containing 10 mol% SL were prepared by brief sonication centrifuged (13,000 rpm × 10 min) and then captured on a Sensor Chip L1 to a final surface density of 3000 to 6000 response units to establish the baseline prior to protein addition. Injections of proteins or buffer were performed at 5 μl/min flow rates as recently described in (48). The setup and wash conditions used for monitoring protein adsorption/desorption were similar to those described in (27).

Phosphoinositide activation of the CPTP GLTP-fold

OPM and HADDOCK modeling

The OPM computational approach was used to identify residues involved in the initial docking of CPTP, ACD11, and GLTP with the membrane interface as shown in Figure 4 and Fig. S5 (54). HADDOCK modeling was used to gain insights into the interaction between PI-(4,5)P₂ and CPTP at the molecular level by docking di-4:0 PI-(4,5)P₂ with the di-Arg motifs in α -helix 6 or the α -3/4 helices connecting loop using HADDOCK 2.4 available online (<https://wenmr.science.uu.nl/haddock2.4>; (69, 70)). HADDOCK-calculated docking interfaces are based on experimental knowledge in the form of AIRs (see Fig. S9). R96/R97 or R155/R156 was designated as active amino acid residues based on experimental data and passive amino acid residues were automatically generated by the program. Illustration, visualization, and analyses of the docked complexes were provided by UCSF Chimera (85) for their interaction studies.

Data availability

All data are contained within the article and the supporting information.

Supporting information—This article contains [supporting information](#).

Acknowledgments—We acknowledge WeNMR Grid resources and European e-Infrastructure projects FP7 WeNMR (project# 261572), H2020 West-Life (project# 675858), and EOSC-hub (project# 777536) for the use of their web portals, available via EGI infrastructure with the dedicated support of CESNET-MetaCloud, INFN-PADOVA, NCG-INGRID-PT, TW-NCHC, SURFsara, and NIKHEF, along with the additional support of the National GRID Initiatives of Belgium, France, Italy, Germany, the Netherlands, Poland, Portugal, Spain, UK, Taiwan, and the US Open Science Grid. The 2017 Biophysical Society Annual Meeting provided a presentation platform for a portion of the data in preliminary form (Zhai *et al.*, *Biophys. J.* 112, 229a, 2017).

Author contributions—Y.-G. G.: investigation, methodology, data curation, formal analysis, visualization, writing—original draft, writing—review and editing; X. Z.: investigation, methodology, formal analysis, visualization, writing—review and editing; I. A. B.: methodology, resources; J. G. M.: methodology, resources; D. J. P.: writing—review and editing; L. M.: visualization, writing—review and editing; R. E. B.: conceptualization, visualization, supervision, project administration, writing—original draft, writing—review and editing, and funding acquisition.

Funding and additional information—The research presented here was supported by NHLBI HL125353, NIGMS GM45928, and NCI CA121493; the Russian Foundation for Basic Research 015-04-07415; Abby Rockefeller Mauze Trust, the Maloris Foundation, and the Hormel Foundation.

Conflict of interest—The authors declare that they have no conflicts of interest with the contents of this article.

Abbreviations—The abbreviations used are: ACD11, accelerated cell death-11; AIR, ambiguous interaction restraint; C1P, ceramide-1-

phosphate; CPTP, ceramide-1-phosphate transfer protein; FRET, fluorescence energy transfer; GLTP, glycolipid transfer protein; LBD, lipid-binding domain; LTP, lipid transfer protein; OPM, orientation of proteins in membranes; ORF, open reading frame; PH, pleckstrin homology; PS, phosphatidylserine; SL, sphingolipid; SPR, surface plasmon resonance.

References

1. de Saint-Jean, M., Delfosse, V., Douguet, D., Chicanne, G., Payrastra, B., Bourguet, W., Antonny, B., and Drin, G. (2011) Osh4p exchanges sterols for phosphatidylinositol 4-phosphate between lipid bilayers. *J. Cell Biol.* **195**, 965–978
2. Grabon, A., Bankaitis, V. A., and McDermott, M. I. (2019) The interface between phosphatidylinositol transfer protein function and phosphoinositide signaling in higher eukaryotes. *J. Lipid Res.* **60**, 242–268
3. Holthuis, J. C., and Menon, A. K. (2014) Lipid landscapes and pipelines in membrane homeostasis. *Nature* **510**, 48–57
4. Lipp, N. F., Ikhlef, S., Milanini, J., and Drin, G. (2020) Lipid exchangers: Cellular functions and mechanistic links with phosphoinositide metabolism. *Front. Cell. Dev. Biol.* **8**, 663
5. Luo, J., Jiang, L. Y., Yang, H., and Song, B. L. (2019) Intracellular cholesterol transport by sterol transfer proteins at membrane contact sites. *Trends Biochem. Sci.* **44**, 273–292
6. Malinina, L., Patel, D. J., and Brown, R. E. (2017) How alpha-helical motifs form functionally diverse lipid-binding compartments. *Annu. Rev. Biochem.* **86**, 609–636
7. Malinina, L., Simanshu, D. K., Zhai, X., Samygin, V. R., Kamlekar, R., Kenoth, R., Ochoa-Lizarralde, B., Malakhova, M. L., Molotkovsky, J. G., Patel, D. J., and Brown, R. E. (2015) Sphingolipid transfer proteins defined by the GLTP-fold. *Q. Rev. Biophys.* **48**, 281–322
8. Mishra, S. K., Gao, Y. G., Zou, X., Stephenson, D. J., Malinina, L., Hinchcliffe, E. H., Chalfant, C. E., and Brown, R. E. (2020) Emerging roles for human glycolipid transfer protein superfamily members in the regulation of autophagy, inflammation, and cell death. *Prog. Lipid Res.* **78**, 101031
9. Olkkonen, V. M., and Li, S. (2013) Oxysterol-binding proteins: Sterol and phosphoinositide sensors coordinating transport, signaling and metabolism. *Prog. Lipid Res.* **52**, 529–538
10. Prinz, W. A. (2014) Bridging the gap: Membrane contact sites in signaling, metabolism, and organelle dynamics. *J. Cell Biol.* **205**, 759–769
11. Wong, L. H., Copic, A., and Levine, T. P. (2017) Advances on the transfer of lipids by lipid transfer proteins. *Trends Biochem. Sci.* **42**, 516–530
12. Wong, L. H., Gatta, A. T., and Levine, T. P. (2019) Lipid transfer proteins: The lipid commute via shuttles, bridges and tubes. *Nat. Rev. Mol. Cell Biol.* **20**, 85–101
13. Kumagai, K., and Hanada, K. (2019) Structure, functions and regulation of CERT, a lipid-transfer protein for the delivery of ceramide at the ER-Golgi membrane contact sites. *FEBS Lett.* **593**, 2366–2377
14. Yamaji, T., and Hanada, K. (2015) Sphingolipid metabolism and inter-organelle transport: Localization of sphingolipid enzymes and lipid transfer proteins. *Traffic* **16**, 101–122
15. Leon, L., Tatituri, R. V., Grenha, R., Sun, Y., Barral, D. C., Minnaard, A. J., Bhowruth, V., Veerapen, N., Besra, G. S., Kasmar, A., Peng, W., Moody, D. B., Grabowski, G. A., and Brenner, M. B. (2012) Saposins utilize two strategies for lipid transfer and CD1 antigen presentation. *Proc. Natl. Acad. Sci. U. S. A.* **109**, 4357–4364
16. Ran, Y., and Fanucci, G. E. (2009) Ligand extraction properties of the GM2 activator protein and its interactions with lipid vesicles. *Biophys. J.* **97**, 257–266
17. Schulze, H., and Sandhoff, K. (2014) Sphingolipids and lysosomal pathologies. *Biochim. Biophys. Acta* **1841**, 799–810
18. Teyton, L. (2018) Role of lipid transfer proteins in loading CD1 antigen-presenting molecules. *J. Lipid Res.* **59**, 1367–1373
19. Brown, R. E., and Mattjus, P. (2007) Glycolipid transfer proteins. *Biochim. Biophys. Acta* **1771**, 746–760

20. Mattjus, P. (2009) Glycolipid transfer proteins and membrane interaction. *Biochim. Biophys. Acta* **1788**, 267–272
21. Mattjus, P. (2016) Specificity of the mammalian glycolipid transfer proteins. *Chem. Phys. Lipids* **194**, 72–78
22. Simanshu, D. K., Kamlekar, R. K., Wijesinghe, D. S., Zou, X., Zhai, X., Mishra, S. K., Molotkovsky, J. G., Malinina, L., Hinchcliffe, E. H., Chalfant, C. E., Brown, R. E., and Patel, D. J. (2013) Non-vesicular trafficking by a ceramide-1-phosphate transfer protein regulates eicosanoids. *Nature* **500**, 463–467
23. Simanshu, D. K., Zhai, X., Munch, D., Hofius, D., Markham, J. E., Bielawski, J., Bielawska, A., Malinina, L., Molotkovsky, J. G., Mundy, J. W., Patel, D. J., and Brown, R. E. (2014) Arabidopsis accelerated cell death 11, ACD11, is a ceramide-1-phosphate transfer protein and intermediary regulator of phytoceramide levels. *Cell Rep.* **6**, 388–399
24. Airene, T. T., Kidron, H., Nymalm, Y., Nylund, M., West, G., Mattjus, P., and Salminen, T. A. (2006) Structural evidence for adaptive ligand binding of glycolipid transfer protein. *J. Mol. Biol.* **355**, 224–236
25. D'Angelo, G., Polishchuk, E., Di Tullio, G., Santoro, M., Di Campli, A., Godi, A., West, G., Bielawski, J., Chuang, C. C., van der Spoel, A. C., Platt, F. M., Hannun, Y. A., Polishchuk, R., Mattjus, P., and De Matteis, M. A. (2007) Glycosphingolipid synthesis requires FAPP2 transfer of glucosylceramide. *Nature* **449**, 62–67
26. Kamlekar, R. K., Simanshu, D. K., Gao, Y. G., Kenoth, R., Pike, H. M., Prendergast, F. G., Malinina, L., Molotkovsky, J. G., Venyaminov, S. Y., Patel, D. J., and Brown, R. E. (2013) The glycolipid transfer protein (GLTP) domain of phosphoinositol 4-phosphate adaptor protein-2 (FAPP2): Structure drives preference for simple neutral glycosphingolipids. *Biochim. Biophys. Acta* **1831**, 417–427
27. Ochoa-Lizarralde, B., Gao, Y. G., Popov, A. N., Samygina, V. R., Zhai, X., Mishra, S. K., Boldyrev, I. A., Molotkovsky, J. G., Simanshu, D. K., Patel, D. J., Brown, R. E., and Malinina, L. (2018) Structural analyses of 4-phosphate adaptor protein 2 yield mechanistic insights into sphingolipid recognition by the glycolipid transfer protein family. *J. Biol. Chem.* **293**, 16709–16723
28. Malinina, L., Malakhova, M. L., Kanack, A. T., Lu, M., Abagyan, R., Brown, R. E., and Patel, D. J. (2006) The liganding of glycolipid transfer protein is controlled by glycolipid acyl structure. *PLoS Biol.* **4**, e362
29. Malinina, L., Malakhova, M. L., Teplov, A., Brown, R. E., and Patel, D. J. (2004) Structural basis for glycosphingolipid transfer specificity. *Nature* **430**, 1048–1053
30. Samygina, V. R., Popov, A. N., Cabo-Bilbao, A., Ochoa-Lizarralde, B., Goni-de-Cerio, F., Zhai, X., Molotkovsky, J. G., Patel, D. J., Brown, R. E., and Malinina, L. (2011) Enhanced selectivity for sulfatide by engineered human glycolipid transfer protein. *Structure* **19**, 1644–1654
31. Halter, D., Neumann, S., van Dijk, S. M., Wolthoorn, J., de Maziere, A. M., Vieira, O. V., Mattjus, P., Klumperman, J., van Meer, G., and Sprong, H. (2007) Pre- and post-Golgi translocation of glucosylceramide in glycosphingolipid synthesis. *J. Cell Biol.* **179**, 101–115
32. Kjellberg, M. A., Backman, A. P., Ohvo-Rekila, H., and Mattjus, P. (2014) Alternation in the glycolipid transfer protein expression causes changes in the cellular lipidome. *PLoS One* **9**, e97263
33. Mishra, S. K., Gao, Y. G., Deng, Y., Chalfant, C. E., Hinchcliffe, E. H., and Brown, R. E. (2018) CPTP: A sphingolipid transfer protein that regulates autophagy and inflammasome activation. *Autophagy* **14**, 862–879
34. Mishra, S. K., Stephenson, D. J., Chalfant, C. E., and Brown, R. E. (2019) Upregulation of human glycolipid transfer protein (GLTP) induces necroptosis in colon carcinoma cells. *Biochim. Biophys. Acta Mol. Cell Biol. Lipids* **1864**, 158–167
35. Stahelin, R. V., Subramanian, P., Vora, M., Cho, W., and Chalfant, C. E. (2007) Ceramide-1-phosphate binds group IVA cytosolic phospholipase $\alpha 2$ via a novel site in the C2 domain. *J. Biol. Chem.* **282**, 20467–20474
36. Ward, K. E., Bhardwaj, N., Vora, M., Chalfant, C. E., Lu, H., and Stahelin, R. V. (2013) The molecular basis of ceramide-1-phosphate recognition by C2 domains. *J. Lipid Res.* **54**, 636–648
37. Cho, W., and Stahelin, R. V. (2005) Membrane-protein interactions in cell signaling and membrane trafficking. *Annu. Rev. Biophys. Biomol. Struct.* **34**, 119–151
38. Corbalan-Garcia, S., and Gomez-Fernandez, J. C. (2014) Signaling through C2 domains: More than one lipid target. *Biochim. Biophys. Acta* **1838**, 1536–1547
39. Hirano, Y., Gao, Y. G., Stephenson, D. J., Vu, N. T., Malinina, L., Simanshu, D. K., Chalfant, C. E., Patel, D. J., and Brown, R. E. (2019) Structural basis of phosphatidylcholine recognition by the C2-domain of cytosolic phospholipase A2 α . *Elife* **8**, e44760
40. Lemmon, M. A. (2008) Membrane recognition by phospholipid-binding domains. *Nat. Rev. Mol. Cell Biol.* **9**, 99–111
41. Moravcevic, K., Oxley, C. L., and Lemmon, M. A. (2012) Conditional peripheral membrane proteins: Facing up to limited specificity. *Structure* **20**, 15–27
42. Stahelin, R. V. (2009) Lipid binding domains: More than simple lipid effectors. *J. Lipid Res.* **50** Suppl., S299–S304
43. Stahelin, R. V., Scott, J. L., and Frick, C. T. (2014) Cellular and molecular interactions of phosphoinositides and peripheral proteins. *Chem. Phys. Lipids* **182**, 3–18
44. Kenoth, R., Brown, R. E., and Kamlekar, R. K. (2019) *In vitro* measurement of sphingolipid intermembrane transport illustrated by GLTP superfamily members. *Methods Mol. Biol.* **1949**, 237–256
45. Schink, K. O., Tan, K. W., and Stenmark, H. (2016) Phosphoinositides in control of membrane dynamics. *Annu. Rev. Cell Dev. Biol.* **32**, 143–171
46. Wen, Y., Vogt, V. M., and Feigenson, G. W. (2018) Multivalent cation-bridged PI(4,5)P2 clusters form at very low concentrations. *Biophys. J.* **114**, 2630–2639
47. Dowler, S., Kular, G., and Alessi, D. R. (2002) Protein lipid overlay assay. *Sci. STKE* **2002**, pl6
48. Zhai, X., Gao, Y. G., Mishra, S. K., Simanshu, D. K., Boldyrev, I. A., Benson, L. M., Bergen, H. R., 3rd, Malinina, L., Mundy, J., Molotkovsky, J. G., Patel, D. J., and Brown, R. E. (2017) Phosphatidylserine stimulates ceramide 1-phosphate (C1P) intermembrane transfer by C1P transfer proteins. *J. Biol. Chem.* **292**, 2531–2541
49. Collins, M. D., and Gordon, S. E. (2013) Short-chain phosphoinositide partitioning into plasma membrane models. *Biophys. J.* **105**, 2485–2494
50. Rao, C. S., Chung, T., Pike, H. M., and Brown, R. E. (2005) Glycolipid transfer protein interaction with bilayer vesicles: Modulation by changing lipid composition. *Biophys. J.* **89**, 4017–4028
51. Rao, C. S., Lin, X., Pike, H. M., Molotkovsky, J. G., and Brown, R. E. (2004) Glycolipid transfer protein mediated transfer of glycosphingolipids between membranes: A model for action based on kinetic and thermodynamic analyses. *Biochemistry* **43**, 13805–13815
52. Johnson, J. L., Erickson, J. W., and Cerione, R. A. (2012) C-terminal diarginine motif of Cdc42 protein is essential for binding to phosphatidylinositol 4,5-bisphosphate-containing membranes and inducing cellular transformation. *J. Biol. Chem.* **287**, 5764–5774
53. Scacioc, A., Schmidt, C., Hofmann, T., Urlaub, H., Kuhnel, K., and Perez-Lara, A. (2017) Structure based biophysical characterization of the PROPPIN Atg18 shows Atg18 oligomerization upon membrane binding. *Sci. Rep.* **7**, 14008
54. Lomize, M. A., Pogozheva, I. D., Joo, H., Mosberg, H. I., and Lomize, A. L. (2012) OPM database and PPM web server: Resources for positioning of proteins in membranes. *Nucleic Acids Res.* **40**, D370–D376
55. Kamlekar, R. K., Gao, Y., Kenoth, R., Molotkovsky, J. G., Prendergast, F. G., Malinina, L., Patel, D. J., Wessels, W. S., Venyaminov, S. Y., and Brown, R. E. (2010) Human GLTP: Three distinct functions for the three tryptophans in a novel peripheral amphitropic fold. *Biophys. J.* **99**, 2626–2635
56. Ohvo-Rekila, H., and Mattjus, P. (2011) Monitoring glycolipid transfer protein activity and membrane interaction with the surface plasmon resonance technique. *Biochim. Biophys. Acta* **1808**, 47–54
57. Killian, J. A., and von Heijne, G. (2000) How proteins adapt to a membrane-water interface. *Trends Biochem. Sci.* **25**, 429–434
58. Li, L., Vorobyov, I., and Allen, T. W. (2013) The different interactions of lysine and arginine side chains with lipid membranes. *J. Phys. Chem. B* **117**, 11906–11920
59. MacCallum, J. L., and Tieleman, D. P. (2011) Hydrophobicity scales: A thermodynamic looking glass into lipid-protein interactions. *Trends Biochem. Sci.* **36**, 653–662

Phosphoinositide activation of the CPTP GLTP-fold

60. D'Angelo, G., Uemura, T., Chuang, C. C., Polishchuk, E., Santoro, M., Ohvo-Rekila, H., Sato, T., Di Tullio, G., Varriale, A., D'Auria, S., Daniele, T., Capuani, F., Johannes, L., Mattjus, P., Monti, M., *et al.* (2013) Vesicular and non-vesicular transport feed distinct glycosylation pathways in the Golgi. *Nature* **501**, 116–120
61. Mattjus, P., Molotkovsky, J. G., Smaby, J. M., and Brown, R. E. (1999) A fluorescence resonance energy transfer approach for monitoring protein-mediated glycolipid transfer between vesicle membranes. *Anal. Biochem.* **268**, 297–304
62. Wong, M., Brown, R. E., Barenholz, Y., and Thompson, T. E. (1984) Glycolipid transfer protein from bovine brain. *Biochemistry* **23**, 6498–6505
63. Rovina, P., Jaritz, M., Hofinger, S., Graf, C., Devay, P., Billich, A., Baumrucker, T., and Bornancin, F. (2006) A critical beta6-beta7 loop in the pleckstrin homology domain of ceramide kinase. *Biochem. J.* **400**, 255–265
64. Lamour, N. F., Stahelin, R. V., Wijesinghe, D. S., Maceyka, M., Wang, E., Allegood, J. C., Merrill, A. H., Jr., Cho, W., and Chalfant, C. E. (2007) Ceramide kinase uses ceramide provided by ceramide transport protein: Localization to organelles of eicosanoid synthesis. *J. Lipid Res.* **48**, 1293–1304
65. Falkenburger, B. H., Jensen, J. B., Dickson, E. J., Suh, B. C., and Hille, B. (2010) Phosphoinositides: Lipid regulators of membrane proteins. *J. Physiol.* **588**, 3179–3185
66. Hammond, G. R., Machner, M. P., and Balla, T. (2014) A novel probe for phosphatidylinositol 4-phosphate reveals multiple pools beyond the Golgi. *J. Cell Biol.* **205**, 113–126
67. Dickson, E. J., Jensen, J. B., and Hille, B. (2014) Golgi and plasma membrane pools of PI(4)P contribute to plasma membrane PI(4,5)P2 and maintenance of KCNQ2/3 ion channel current. *Proc. Natl. Acad. Sci. U. S. A.* **111**, E2281–E2290
68. Picas, L., Gaits-Iacovoni, F., and Goud, B. (2016) The emerging role of phosphoinositide clustering in intracellular trafficking and signal transduction. *F1000Res.* **5**, F1000 Faculty Rev-422
69. de Vries, S. J., van Dijk, M., and Bonvin, A. M. (2010) The HADDOCK web server for data-driven biomolecular docking. *Nat. Protoc.* **5**, 883–897
70. van Zundert, G. C. P., Rodrigues, J., Trellet, M., Schmitz, C., Kastiris, P. L., Karaca, E., Melquiond, A. S. J., van Dijk, M., de Vries, S. J., and Bonvin, A. (2016) The HADDOCK2.2 web server: User-friendly integrative modeling of biomolecular complexes. *J. Mol. Biol.* **428**, 720–725
71. Balla, T. (2013) Phosphoinositides: Tiny lipids with giant impact on cell regulation. *Physiol. Rev.* **93**, 1019–1137
72. Guillen, J., Ferrer-Orta, C., Buxaderas, M., Perez-Sanchez, D., Guerrero-Valero, M., Luengo-Gil, G., Pous, J., Guerra, P., Gomez-Fernandez, J. C., Verdaguer, N., and Corbalan-Garcia, S. (2013) Structural insights into the Ca²⁺ and PI(4,5)P₂ binding modes of the C2 domains of rabphilin 3A and synaptotagmin I. *Proc. Natl. Acad. Sci. U. S. A.* **110**, 20503–20508
73. Hansen, S. B., Tao, X., and MacKinnon, R. (2011) Structural basis of PIP₂ activation of the classical inward rectifier K⁺ channel Kir2.2. *Nature* **477**, 495–498
74. Jian, X., Tang, W. K., Zhai, P., Roy, N. S., Luo, R., Gruschus, J. M., Yohe, M. E., Chen, P. W., Li, Y., Byrd, R. A., Xia, D., and Randazzo, P. A. (2015) Molecular basis for cooperative binding of anionic phospholipids to the PH domain of the Arf GAP ASAP1. *Structure* **23**, 1977–1988
75. Tan, X., Thapa, N., Choi, S., and Anderson, R. A. (2015) Emerging roles of PtdIns(4,5)P₂—beyond the plasma membrane. *J. Cell Sci.* **128**, 4047–4056
76. Thompson, P. M., Ramachandran, S., Case, L. B., Tolbert, C. E., Tandon, A., Pershad, M., Dokholyan, N. V., Waterman, C. M., and Campbell, S. L. (2017) A structural model for vinculin insertion into PIP₂-containing membranes and the effect of insertion on vinculin activation and localization. *Structure* **25**, 264–275
77. Bergelson, L. D., Molotkovsky, J. G., and Manevich, Y. M. (1985) Lipid-specific fluorescent probes in studies of biological membranes. *Chem. Phys. Lipids* **37**, 165–195
78. Molotkovsky, J. G., Mikhalyov, I. I., Imbs, A. B., and Bergelson, L. D. (1991) Synthesis and characterization of new fluorescent glycolipid probes - molecular-organization of glycosphingolipids in mixed-composition lipid bilayers. *Chem. Phys. Lipids* **58**, 199–212
79. Boldyrev, I. A., Brown, R. E., and Molotkovsky, J. G. (2013) An expedient synthesis of fluorescent labeled ceramide-1-phosphate analogues. *Russ. J. Bioorg. Chem.* **39**, 539–542
80. Lin, X., Mattjus, P., Pike, H. M., Windebank, A. J., and Brown, R. E. (2000) Cloning and expression of glycolipid transfer protein from bovine and porcine brain. *J. Biol. Chem.* **275**, 5104–5110
81. Li, X. M., Malakhova, M. L., Lin, X., Pike, H. M., Chung, T., Molotkovsky, J. G., and Brown, R. E. (2004) Human glycolipid transfer protein: Probing conformation using fluorescence spectroscopy. *Biochemistry* **43**, 10285–10294
82. Malakhova, M. L., Malinina, L., Pike, H. M., Kanack, A. T., Patel, D. J., and Brown, R. E. (2005) Point mutational analysis of the liganding site in human glycolipid transfer protein. Functionality of the complex. *J. Biol. Chem.* **280**, 26312–26320
83. Brown, R. E. (1990) Spontaneous transfer of lipids between membranes. *Subcell. Biochem.* **16**, 333–363
84. Brown, R. E. (1992) Spontaneous lipid transfer between organized lipid assemblies. *Biochim. Biophys. Acta* **1113**, 375–389
85. Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., and Ferrin, T. E. (2004) UCSF Chimera—a visualization system for exploratory research and analysis. *J. Comput. Chem.* **25**, 1605–1612